Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
- PMID: 32703906
- PMCID: PMC7402631
- DOI: 10.1126/science.abd0826
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has led to accelerated efforts to develop therapeutics and vaccines. A key target of these efforts is the spike (S) protein, which is metastable and difficult to produce recombinantly. We characterized 100 structure-guided spike designs and identified 26 individual substitutions that increased protein yields and stability. Testing combinations of beneficial substitutions resulted in the identification of HexaPro, a variant with six beneficial proline substitutions exhibiting higher expression than its parental construct (by a factor of 10) as well as the ability to withstand heat stress, storage at room temperature, and three freeze-thaw cycles. A cryo-electron microscopy structure of HexaPro at a resolution of 3.2 angstroms confirmed that it retains the prefusion spike conformation. High-yield production of a stabilized prefusion spike protein will accelerate the development of vaccines and serological diagnostics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Figures




Update of
-
Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes.bioRxiv [Preprint]. 2020 May 30:2020.05.30.125484. doi: 10.1101/2020.05.30.125484. bioRxiv. 2020. Update in: Science. 2020 Sep 18;369(6510):1501-1505. doi: 10.1126/science.abd0826. PMID: 32577660 Free PMC article. Updated. Preprint.
Similar articles
-
Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes.bioRxiv [Preprint]. 2020 May 30:2020.05.30.125484. doi: 10.1101/2020.05.30.125484. bioRxiv. 2020. Update in: Science. 2020 Sep 18;369(6510):1501-1505. doi: 10.1126/science.abd0826. PMID: 32577660 Free PMC article. Updated. Preprint.
-
SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.Emerg Microbes Infect. 2020 Dec;9(1):2076-2090. doi: 10.1080/22221751.2020.1821583. Emerg Microbes Infect. 2020. PMID: 32897177 Free PMC article.
-
The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.Cells. 2020 Oct 22;9(11):2343. doi: 10.3390/cells9112343. Cells. 2020. PMID: 33105869 Free PMC article. Review.
-
Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation.Nat Struct Mol Biol. 2020 Oct;27(10):942-949. doi: 10.1038/s41594-020-0483-8. Epub 2020 Aug 4. Nat Struct Mol Biol. 2020. PMID: 32753755 Free PMC article.
-
The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens.Front Immunol. 2020 Oct 7;11:576622. doi: 10.3389/fimmu.2020.576622. eCollection 2020. Front Immunol. 2020. PMID: 33117378 Free PMC article. Review.
Cited by
-
Effective high-throughput isolation of fully human antibodies targeting infectious pathogens.Nat Protoc. 2021 Jul;16(7):3639-3671. doi: 10.1038/s41596-021-00554-w. Epub 2021 May 25. Nat Protoc. 2021. PMID: 34035500 Review.
-
Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses in vivo and Inhibit Viral Replication in vitro.Front Immunol. 2021 Mar 26;12:613045. doi: 10.3389/fimmu.2021.613045. eCollection 2021. Front Immunol. 2021. PMID: 33841395 Free PMC article.
-
An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits.J Virol. 2024 Feb 20;98(2):e0162323. doi: 10.1128/jvi.01623-23. Epub 2024 Jan 9. J Virol. 2024. PMID: 38193692 Free PMC article.
-
Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge.Nat Commun. 2024 Feb 20;15(1):1553. doi: 10.1038/s41467-024-45404-x. Nat Commun. 2024. PMID: 38378768 Free PMC article.
-
A systematic review of SARS-CoV-2 vaccine candidates.Signal Transduct Target Ther. 2020 Oct 13;5(1):237. doi: 10.1038/s41392-020-00352-y. Signal Transduct Target Ther. 2020. PMID: 33051445 Free PMC article.
References
-
- Chan J. F. W., Yuan S., Kok K. H., To K. K. W., Chu H., Yang J., Xing F., Liu J., Yip C. C. Y., Poon R. W. S., Tsoi H. W., Lo S. K. F., Chan K. H., Poon V. K. M., Chan W. M., Ip J. D., Cai J. P., Cheng V. C. C., Chen H., Hui C. K. M., Yuen K. Y., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet 395, 514–523 (2020). 10.1016/S0140-6736(20)30154-9 - DOI - PMC - PubMed
-
- Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020). 10.1016/S0140-6736(20)30183-5 - DOI - PMC - PubMed
-
- Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., Schiergens T. S., Herrler G., Wu N. H., Nitsche A., Müller M. A., Drosten C., Pöhlmann S., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271–280.e8 (2020). 10.1016/j.cell.2020.02.052 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous